Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18828272rdf:typepubmed:Citationlld:pubmed
pubmed-article:18828272lifeskim:mentionsumls-concept:C1134719lld:lifeskim
pubmed-article:18828272lifeskim:mentionsumls-concept:C1527349lld:lifeskim
pubmed-article:18828272lifeskim:mentionsumls-concept:C0030190lld:lifeskim
pubmed-article:18828272lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:18828272lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:18828272lifeskim:mentionsumls-concept:C1522609lld:lifeskim
pubmed-article:18828272lifeskim:mentionsumls-concept:C1554112lld:lifeskim
pubmed-article:18828272pubmed:issue3lld:pubmed
pubmed-article:18828272pubmed:dateCreated2008-10-2lld:pubmed
pubmed-article:18828272pubmed:abstractTextThe study group was derived from the archive materials of 55 invasive ductal breast cancer (IDC) patients who had undergone breast-preserving surgery (partial mastectomy/ axillary dissection). All patients included in the study had clinically T(1)-2, N0-M0 invasive ductal carcinoma. Genomic DNA species were extracted from paraffin-embedded blocks, and plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G genotyping was done by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). Patient demographics, axillary metastasis status, metastatic lymph nodi/total dissected lymph nodes from axilla, histopathologic characteristics of tumors, local recurrences, and survival ratio were assessed. PAI-1 4G/5G genotype frequencies were 4G/4G (64%), 4G/5G (31%), and 5G/5G (5%) in the patient group. According to the results based on frequencies, the demographics were not different. Five-year local recurrence rate of 4G/5G patients was the lowest (2/17, 12%) (P = 0.02). Also five-year distant metastases ratio of 4G/5G patients was the highest (18%) (P = 0.01). Five- and 10-year disease-free survival rates for the 4G/4G, 4G/5G, and 5G/5G groups were 97% and 94%, 82% and 77%, and 100% and 94%, respectively (P = 0.004). The results of this study indicate that the 4G allele in the PAI 1 gene had a negative impact on local recurrence and disease-free survival of patients with clinical T(1)-2N0M0 IDC.lld:pubmed
pubmed-article:18828272pubmed:languageenglld:pubmed
pubmed-article:18828272pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18828272pubmed:citationSubsetIMlld:pubmed
pubmed-article:18828272pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18828272pubmed:statusMEDLINElld:pubmed
pubmed-article:18828272pubmed:issn0020-8868lld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:HaberalMMlld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:OzbekNNlld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:KarakayaliHHlld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:IsiklarIIlld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:OzdemirB HBHlld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:TutarN UNUlld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:YagmurdurM...lld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:VerdiHHlld:pubmed
pubmed-article:18828272pubmed:authorpubmed-author:AtacF BFBlld:pubmed
pubmed-article:18828272pubmed:issnTypePrintlld:pubmed
pubmed-article:18828272pubmed:volume93lld:pubmed
pubmed-article:18828272pubmed:ownerNLMlld:pubmed
pubmed-article:18828272pubmed:authorsCompleteYlld:pubmed
pubmed-article:18828272pubmed:pagination163-8lld:pubmed
pubmed-article:18828272pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:meshHeadingpubmed-meshheading:18828272...lld:pubmed
pubmed-article:18828272pubmed:articleTitlePrognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.lld:pubmed
pubmed-article:18828272pubmed:affiliationDepartment of General Surgery, Baskent University Faculty of Medicine, Ankara, Turkey.lld:pubmed
pubmed-article:18828272pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18828272pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:5054entrezgene:pubmedpubmed-article:18828272lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18828272lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18828272lld:entrezgene